Abstract

Pharmacophore modeling is usually considered as a special type of virtual screening without probabilistic nature. Correspondence of at least one conformation of a molecule to pharmacophore is considered as evidence of its bioactivity. We show that pharmacophores can be treated as one-class machine learning models, and the probability the reflecting model’s confidence can be assigned to a pharmacophore on the basis of their precision of active compounds identification on a calibration set. Two schemes (Max and Mean) of probability calculation for consensus prediction based on individual pharmacophore models were proposed. Both approaches to some extent correspond to commonly used consensus approaches like the common hit approach or the one based on a logical OR operation uniting hit lists of individual models. Unlike some known approaches, the proposed ones can rank compounds retrieved by multiple models. These approaches were benchmarked on multiple ChEMBL datasets used for ligand-based pharmacophore modeling and externally validated on corresponding DUD-E datasets. The influence of complexity of pharmacophores and their performance on a calibration set on results of virtual screening was analyzed. It was shown that Max and Mean approaches have superior early enrichment to the commonly used approaches. Thus, a well-performing, easy-to-implement, and probabilistic alternative to existing approaches for pharmacophore-based virtual screening was proposed.

Highlights

  • Pharmacophore modeling is a widely used approach for the discovery of new biologically active compounds

  • Pharmacophore modeling is considered as a special type of virtual screening without a probabilistic nature

  • Pharmacophore modeling is a chemistry-specific one-class classification method based on abstraction of 3D structure of molecules as a set of features with a given spatial orientation that can be recognized by a target biomolecule

Read more

Summary

Introduction

Pharmacophore modeling is a widely used approach for the discovery of new biologically active compounds. [1] Once such pharmacophore is found, the task is to find a compound that has the same arrangement of interaction centers, called pharmacophore features, in at least one of the low-energy conformations. This process being done in silico is called pharmacophore-based virtual screening. A single pharmacophore model was commonly used for virtual screening [4,5]. This model could be derived from a structure of a ligand–protein complex or could be generated from a set of known active compounds. Seven known antibacterial compounds that inhibit bacterial RNA polymerase and have different binding modes were flexibly aligned to find a pharmacophore matching a common binding mode

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call